Nasdaq 100, FTSE 100, S&P 500, Dow Jones Industrial Average. Read Richard J. Hunter's latest article on Investing.com UK.

Read More »

Hikma shares fall as margins disappoint, despite revenue beat

However, Hikma’s core EBIT for the year stood at $719 million, with a margin of 22.8%, slightly below the consensus estimate of 23.4%. Hikma’s 2H24 results showed a 3% sales beat, primarily driven by ...

Read More »

Investing in Hikma Pharmaceuticals (LON:HIK) five years ago would have delivered you a 38% gain

For example, the Hikma Pharmaceuticals PLC (LON:HIK) share price is up 23% in the last 5 years, clearly besting the market return of around 3.1% (ignoring dividends). However, more recent returns ...

Read More »

Investing in Hikma Pharmaceuticals (LON:HIK) five years ago would have delivered you a 38% gain

For example, the Hikma Pharmaceuticals PLC (LON:HIK) share price is up 23% in the last 5 years, clearly besting the market return of around 3.1% (ignoring dividends). However, more recent returns ...

Read More »

Hikma Pharmaceuticals PLC (HIK.L)

In this article, we are going to take a look at where Hikma Pharmaceuticals PLC (LON:HIK.L) stands against the other U.K. dividend aristocrats. In recent years, investors have turned away from UK ...

Read More »